Bizarre Patents
A simulation environment for the sport of boxing utilizing a robotic machine interface system which carries a person
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7258997 | Methods of increasing protein expression levels The present invention relates to methods of increasing protein expression levels whereby at least one amino acid in a protein amino acid sequence is substituted for the amino acid, proline. Preferably, the substitution occurs within 15 amino acids, more preferably w... | 08/21/2007 |
| 7118750 | Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more peptide fragments of the human TNFα molecule has been substituted by one... | 10/10/2006 |
| 6930097 | Matrix metalloproteinase and tumor necrosis factor inhibitors A compound of formula 1-[3,4-dihydroxy-5-(2-hydroxyethyl)tetrahydrofuran-2-yl]pryimidine-2,4(1H,3H)-dione has inhibitory effects of matrix metalloproteinase-2 (gelatinase A) enzyme and binding of TNFα to TNFα-RI. ... | 08/16/2005 |
| 6683060 | Matrix metalloproteinase and tumor necrosis factor inhibitors The invention discloses methods of treatment and prevention for TNF-related disorders and MMP-related disorders and compounds useful in such treatments. In particular, the invention dislcoses pharmaceutical compositions comprising a compound of the... | 01/27/2004 |
| 6635743 | Apoptosis inducing molecule II and methods of use The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors,... | 10/21/2003 |
| 6479254 | Apoptosis inducing molecule II The present invention relates to a novel member of the TNF-Ligand superfamily, Apoptosis Inducing Molecule II (AIM II). In particular, isolated nucleic acid molecules are provided encoding the human AIM II protein. AIM II polypeptides are also provided as... | 11/12/2002 |
| 6271346 | TNF Receptors, TNF binding proteins and DNAs coding for them DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. R... | 08/07/2001 |
| 6127528 | Process for adsorbing and removing tumor necrosis factor- The present invention relates to an adsorbent being capable of efficiently removing tumor necrosis factor- (TNF-) in a body fluid, an adsorber using the adsorbent and a process for adsorbing and removing TNF-, namely an adsorbent of T... | 10/03/2000 |
| 6030945 | Apo-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and an... | 02/29/2000 |
| 5889156 | TNF deletion muteins A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that en... | 03/30/1999 |
| 5698518 | Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists A method of treating patients to inhibit inflammation is disclosed. In the method, an effective amount of calmodulin, a calmodulin analogue or calmodulin receptor agonist is administered to a patient to inhibit production of tumor necrosis factor and/or a... | 12/16/1997 |
| 5370870 | Method for protection against reactive oxygen species Methods suitable for the protection inhibtion and prevention of the deleterious effects of reactive oxygen species are provided, wherein an effective amount of a protective agent(s) selected from the group of tumor necrosis factor-alpha and -beta, growth ... | 12/06/1994 |
| 5298603 | GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use Expression of a gene coding for human granulocyte macrophage colony-stimulating factor (CSF) in bacteria results in CSF proteins which are biologically active. Modification of the natural or of a synthetic gene structure results in biologically active der... | 03/29/1994 |
| 5288852 | Human tumor necrosis factor polypeptides A novel cloned DNA encoding a human tumor necrosis factor (TNF), a vector having said DNA inserted thereinto, a host transformed with said vector and a novel human TNF polypeptide, and processes for producing them.... | 02/22/1994 |
| 5247070 | N-terminal muteins of tumor necrosis factor A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its mutein, wherein the amino acid sequence of the 1st Ser to the... | 09/21/1993 |
| 5200176 | Method for protection of ischemic tissues using tumor nerosis factor Methods suitable for the protection, inhibition and prevention the deleterious effects of reactive oxygen species are provided, wherein an effective amount of a tumor necrosis factor is administered. Pretreatment of tissues and organs to be transplanted i... | 04/06/1993 |
| 5180811 | Proteins having a TNF action comprising TNF-fibromectin fusion protein Derivatives of a tumor necrosis factor (TNF), which originate from a modification at the amino terminus of the TNF molecule are suitable for controlling diseases.... | 01/19/1993 |
| 5157106 | N-terminal deletions of lymphotoxin, their preparation and use Polypeptides which differ from lymphotoxin by the absence of amino acids at the N-terminal end of the lymphotoxin are described. The polypeptides can be prepared by gene manipulation and are suitable, alone or in combination with lymphokines, as pharmaceu... | 10/20/1992 |
| 4871663 | Exporession vector for human TnF The present invention provides a vector plasmid capable of efficient tumor necrosis factor (TNF) production, a process capable of efficient TNF production in a host transformed with said plasmid and a composition containing the TNF produced by said proces... | 10/03/1989 |
| 4777241 | Proteinaceous substance showing antitumorous action and its preparing method A proteinaceous substance having the following biochemical characteristics: (A) a strong cytolytic activity against mouse tumor cells L-929, but not cytotoxic activity for normal cells such as human fetus fibroblasts, human adult skin fibroblasts and chinese h... | 10/11/1988 |
| 4684623 | Use of tumor necrosis factor as a weight regulator A method for controlling weight by suppressing the normal metabolism of adipose tissue is disclosed. Administration of tumor necrosis factor (TNF) or a pharmaceutical composition containing it results in suppression of anabolism of adipose cells.... | 08/04/1987 |
| 4677063 | Human tumor necrosis factor Human tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obta... | 06/30/1987 |
| 4677064 | Human tumor necrosis factor Human Tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obta... | 06/30/1987 |
| 4677197 | Purification method for tumor necrosis factor An improved method for purifying TNF, especially recombinantly produced TNF in bacteria, is disclosed. The purification employs a hydrophobic support in a chromatographic column which is then developed, preferably by HPLC. Preliminary purifications using ... | 06/30/1987 |
| 4650674 | Synergistic cytotoxic composition Compositions comprising an interferon and a cytotoxic protein designated tumor necrosis factor exhibit a synergistic cytotoxic effect on tumor cells.... | 03/17/1987 |
| 4582821 | Inhibition of cyclic nucleotide independent protein kinases Peptide and amino acid halomethyl ketones are employed in processes for inhibiting cyclic nucleotide independent protein kinase activity and tumor cell growth.... | 04/15/1986 |
| 4360458 | Antitumor antibacterial agents An antitumor antibacterial complex referred to as BBM-928 is described which is produced by microbiological fermentation under controlled conditions using a species of actinomycetes. The bioactive components of the complex have pronounced antitumor activi... | 11/23/1982 |
